Telik cancer drug fails trials; stock plummets
(Reuter
Reuters - Telik Inc. said on Tuesday that its
experimental cancer drug failed to improve survival in patients
with advanced lung cancer or in patients with ovarian cancer,
sending its stock plunging nearly 70 percent.
Stumble It!
Tweet This
Bookmark on Delicious
Share on Facebook
Share on MySpace